Senator Richard Blumenthal (Democratic-Connecticut) recently sold part of their stake in Oncology Institute, Inc. (NASDAQ:STLN). In a filing disclosed on October 26th, the Senator disclosed that they had sold between $1,001 and $15,000 in Oncology Institute stock on September 18th.
Senator Richard Blumenthal also recently made the following trade(s):
- Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/23/2026.
- Sold $15,001 – $50,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/22/2026.
- Sold $1,001 – $15,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/22/2026.
- Sold $15,001 – $50,000 in shares of Oncology Institute (NASDAQ:STLN) on 9/18/2026.
Oncology Institute Stock Performance
Shares of STLN opened at $6.64 on Thursday. The firm has a market capitalization of $656.29 million, a PE ratio of -22.13 and a beta of 0.39. Oncology Institute, Inc. has a 12 month low of $2.32 and a 12 month high of $7.13. The stock’s 50-day moving average is $6.47.
Oncology Institute (NASDAQ:STLN – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.08) EPS for the quarter. The company had revenue of $161.28 million during the quarter, compared to analysts’ expectations of $152.80 million. As a group, analysts predict that Oncology Institute, Inc. will post -0.21 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of research firms have recently issued reports on STLN. BTIG Research lifted their price objective on shares of Oncology Institute from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. Lake Street Capital assumed coverage on shares of Oncology Institute in a research note on Monday, July 6th. They issued a “buy” rating and a $10.00 target price for the company. Weiss Ratings began coverage on shares of Oncology Institute in a research note on Thursday, August 6th. They issued a “sell (d-)” rating for the company. Finally, Needham & Company LLC raised their price target on shares of Oncology Institute from $7.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, October 14th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $9.00.
Get Our Latest Analysis on Oncology Institute
Hedge Funds Weigh In On Oncology Institute
Large investors have recently added to or reduced their stakes in the company. State Street Corp acquired a new position in Oncology Institute in the second quarter worth $8,432,000. The Manufacturers Life Insurance Company bought a new stake in Oncology Institute during the second quarter valued at $111,000. WINTON GROUP Ltd bought a new stake in Oncology Institute during the second quarter valued at $102,000. Engineers Gate Manager LP acquired a new stake in shares of Oncology Institute during the second quarter worth $67,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Oncology Institute during the second quarter worth $396,000. 36.86% of the stock is currently owned by institutional investors.
Insider Transactions at Oncology Institute
In related news, Director Brad Hively sold 298,853 shares of the business’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $6.51, for a total transaction of $1,945,533.03. Following the completion of the sale, the director owned 411,976 shares of the company’s stock, valued at $2,681,963.76. This represents a 42.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, major shareholder Jorey Chernett bought 12,000 shares of the business’s stock in a transaction on Friday, August 14th. The stock was acquired at an average cost of $6.54 per share, for a total transaction of $78,480.00. Following the acquisition, the insider directly owned 10,660,858 shares of the company’s stock, valued at $69,722,011.32. The trade was a 0.11% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Company insiders own 4.40% of the company’s stock.
About Senator Blumenthal
Richard Blumenthal (Democratic Party) is a member of the U.S. Senate from Connecticut. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Blumenthal (Democratic Party, Working Families Party) ran for re-election to the U.S. Senate to represent Connecticut. He won in the general election on November 8, 2022. Before his election to the Senate, Blumenthal had served as the Connecticut Attorney General since 1991. He served in the Connecticut State Senate from 1987 to 1991 and in the Connecticut House of Representatives from 1984 to 1987. As of a 2014 analysis of multiple outside rankings, Blumenthal is one of the most reliable Democratic votes, meaning he can be considered a safe vote for the Democratic Party in Congress.
Oncology Institute Company Profile
The Oncology Institute is a value-based oncology care company focused on delivering comprehensive cancer treatment and related services through community-based care settings. Its model is designed to support patients throughout the cancer-care journey while coordinating treatment among oncologists, primary-care providers, specialists and other healthcare professionals.
The company provides medical oncology and hematology services, cancer screening and diagnosis, treatment planning, chemotherapy and other infusion therapies, supportive care, survivorship services and care-management programs.
Featured Articles
- Five stocks we like better than Oncology Institute
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
- Why Tesla’s Upside Is About More Than a SpaceX Merger
Receive News & Ratings for Oncology Institute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Institute and related companies with MarketBeat.com's FREE daily email newsletter.
